
## **Emmanuel Chatelus**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5917952/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab. Lancet Rheumatology, The, 2022, 4, e13-e16.	2.2	40
2	Management of nonviral mixed cryoglobulinemia vasculitis refractory to rituximab: Data from a European collaborative study and review of the literature. Autoimmunity Reviews, 2022, 21, 103034.	2.5	8
3	Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial. Lancet Rheumatology, The, 2022, 4, e24-e32.	2.2	34
4	Patient preferences for the treatment of systemic sclerosis-associated interstitial lung disease: a discrete choice experiment. Rheumatology, 2022, 61, 4035-4046.	0.9	6
5	Effect of SARS-CoV-2 Vaccination on Symptoms from Post-Acute Sequelae of COVID-19: Results from the Nationwide VAXILONG Study. Vaccines, 2022, 10, 46.	2.1	28
6	Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus. Rheumatology, 2021, 60, 1410-1418.	0.9	20
7	Systemic sclerosis overlap and non-overlap syndromes share clinical characteristics but differ in prognosis and treatments. Seminars in Arthritis and Rheumatism, 2021, 51, 36-42.	1.6	16
8	Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial. Lancet Respiratory Medicine,the, 2021, 9, 295-304.	5.2	232
9	Vaccination against COVID-19: Expectations and concerns of patients with autoimmune and rheumatic diseases. Lancet Rheumatology, The, 2021, 3, e243-e245.	2.2	97
10	Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2021, 9, 522-532.	5.2	195
11	Cluster analysis reveals three main patterns of beliefs and intention with respect to SARS-CoV-2 vaccination in patients with autoimmune and inflammatory diseases. Rheumatology, 2021, 60, SI68-SI76.	0.9	24
12	Rheumatic presentations of Guillain–Barré syndrome as a diagnostic challenge: A case series. Joint Bone Spine, 2021, 88, 105144.	0.8	1
13	COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatology, The, 2021, 3, e419-e426.	2.2	211
14	Incidence and predictors of COVID-19 and flares in patients with rare autoimmune diseases: a systematic survey and serological study at a national reference center in France. Arthritis Research and Therapy, 2021, 23, 188.	1.6	9
15	Refining "Long-COVID―by a Prospective Multimodal Evaluation of Patients with Long-Term Symptoms Attributed to SARS-CoV-2 Infection. Infectious Diseases and Therapy, 2021, 10, 1747-1763.	1.8	55
16	B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics. Annals of the Rheumatic Diseases, 2021, , annrheumdis-2021-220549.	0.5	18
17	Le défi diagnostique des présentations rhumatologiques du syndrome de Guillain-BarréÂ: huit cas. Revue Du Rhumatisme (Edition Francaise), 2021, 88, 382-386.	0.0	0
18	Interleukin 6 receptor inhibition in primary Sjögren syndrome: a multicentre double-blind randomised placebo-controlled trial. Annals of the Rheumatic Diseases, 2021, 80, 329-338.	0.5	61

#	Article	IF	CITATIONS
19	Application of the OMERACT synovitis ultrasound scoring system in juvenile idiopathic arthritis: a multicenter reliability exercise. Rheumatology, 2021, 60, 3579-3587.	0.9	11
20	Acute renal failure in systemic sclerosis revealing Goodpasture syndrome: "All that glitters is not scleroderma renal crisis― Journal of Scleroderma and Related Disorders, 2020, 5, NP1-NP5.	1.0	1
21	T1 mapping cardiac magnetic resonance imaging frequently detects subclinical diffuse myocardial fibrosis in systemic sclerosis patients. Seminars in Arthritis and Rheumatism, 2020, 50, 128-134.	1.6	23
22	Incidence and risk factors for gangrene in patients with systemic sclerosis from the EUSTAR cohort. Rheumatology, 2020, 59, 2016-2023.	0.9	14
23	How and why are rheumatologists relevant to COVID-19?. Joint Bone Spine, 2020, 87, 279-280.	0.8	7
24	A mouse model of MSU-induced acute inflammation <i>in vivo</i> suggests imiquimod-dependent targeting of <i>ll-1î²</i> as relevant therapy for gout patients. Theranostics, 2020, 10, 2158-2171.	4.6	28
25	Worldwide trends in all-cause mortality of auto-immune systemic diseases between 2001 and 2014. Autoimmunity Reviews, 2020, 19, 102531.	2.5	79
26	Risk factors for hydroxychloroquine retinopathy in systemic lupus erythematosus: a case–control study with hydroxychloroquine blood-level analysis. Rheumatology, 2020, 59, 3807-3816.	0.9	24
27	Unique tophus pseudotumoral. Revue Du Rhumatisme (Edition Francaise), 2019, 86, 307.	0.0	0
28	Single tumor-like tophus. Joint Bone Spine, 2019, 86, 509-510.	0.8	1
29	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2019, 71, 1553-1570.	2.9	75
30	Diagnostic performance of temporal artery ultrasound for the diagnosis of giant cell arteritis: a systematic review and meta-analysis of the literature. Autoimmunity Reviews, 2019, 18, 56-61.	2,5	67
31	Patient acceptable symptom state and minimal clinically important difference for patient-reported outcomes in systemic sclerosis: A secondary analysis of a randomized controlled trial comparing personalized physical therapy to usual care. Seminars in Arthritis and Rheumatism, 2019, 48, 694-700.	1.6	18
32	Malignancies in Patients with Anti-RNA Polymerase III Antibodies and Systemic Sclerosis: Analysis of the EULAR Scleroderma Trials and Research Cohort and Possible Recommendations for Screening. Journal of Rheumatology, 2017, 44, 639-647.	1.0	93
33	Risk of autoimmune diseases and human papilloma virus (HPV) vaccines: Six years of case-referent surveillance. Journal of Autoimmunity, 2017, 79, 84-90.	3.0	67
34	Intravenous immunoglobulins in systemic sclerosis: Data from a French nationwide cohort of 46 patients and review of the literature. Autoimmunity Reviews, 2017, 16, 377-384.	2.5	49
35	Mapping and predicting mortality from systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1897-1905.	0.5	410
36	Lumbar Spine Chondrocalcinosis. Journal of Rheumatology, 2017, 44, 1288-1289.	1.0	7

**EMMANUEL CHATELUS** 

#	Article	IF	CITATIONS
37	Personalized Physical Therapy Versus Usual Care for Patients With Systemic Sclerosis: A Randomized Controlled Trial. Arthritis Care and Research, 2017, 69, 1050-1059.	1.5	52
38	Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patients. RMD Open, 2017, 3, e000555.	1.8	20
39	Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Annals of the Rheumatic Diseases, 2016, 75, 1009-1015.	0.5	112
40	Brief Report: Spatial Heterogeneity of Systemic Sclerosis in France: High Prevalence in the Northeast Region. Arthritis and Rheumatology, 2016, 68, 1731-1737.	2.9	13
41	Chloroma—An Uncommon Cause of Arthritis. Arthritis and Rheumatology, 2015, 67, 2239-2239.	2.9	1
42	Outcome of Hepatitis E Virus Infection in Patients With Inflammatory Arthritides Treated With Immunosuppressants. Medicine (United States), 2015, 94, e675.	0.4	50
43	Les effets des régimes et des stratégies diététiques dans la polyarthrite rhumatoÃ⁻de. Revue Du Rhumatisme (Edition Francaise), 2015, 82, 283-290.	0.0	1
44	High reactive oxygen species in fibrotic and nonfibrotic skin of patients with diffuse cutaneous systemic sclerosis. Free Radical Biology and Medicine, 2015, 87, 282-289.	1.3	37
45	Classification criteria and treatment modalities in primary Sjögren's syndrome. Expert Review of Clinical Immunology, 2014, 10, 543-551.	1.3	6
46	When biologics should be used in systemic lupus erythematosus?. Presse Medicale, 2014, 43, e181-e185.	0.8	5
47	Improving agreement in assessment of synovitis in rheumatoid arthritis. Joint Bone Spine, 2013, 80, 155-159.	0.8	12
48	Améliorer le consensus autour de l'évaluation de la synovite dans la polyarthrite rhumatoÃ⁻de. Revue Du Rhumatisme (Edition Francaise), 2013, 80, 238-243.	0.0	0
49	B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Research and Therapy, 2013, 15, R168.	1.6	115
50	<i>Campylobacter fetus</i> infection in three rheumatoid arthritis patients treated with rituximab: Table 1. Annals of the Rheumatic Diseases, 2012, 71, 1094-1095.	0.5	10
51	In antisynthetase syndrome, amyloidosis is rare and might not be related to the disease. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2012, 19, 214-216.	1.4	0
52	Pulmonary arterial hypertension during systemic lupus. Joint Bone Spine, 2012, 79, 205-206.	0.8	1
53	Jessner–Kanof disease induced by leflunomide: a dermal variant of cutaneous lupus?. Rheumatology International, 2011, 31, 255-258.	1.5	16
54	Safety and efficacy of anti–tumor necrosis factor α therapy in ten patients with recentâ€onset refractory reactive arthritis. Arthritis and Rheumatism, 2011, 63, 1274-1280.	6.7	71

#	Article	IF	CITATIONS
55	Whipple Limbic Encephalitis. Archives of Neurology, 2011, 68, 1471.	4.9	15
56	Affections auto-inflammatoiresÂ: critères de diagnostic et de classification. Revue Du Rhumatisme Monographies, 2010, 77, 114-120.	0.0	0
57	Multicentric reticulohistiocytosis: An autoimmune systemic disease? Case report of an association with erosive rheumatoid arthritis and systemic Sjogren syndrome. Joint Bone Spine, 2010, 77, 274-276.	0.8	34
58	Syndrome de Sjögren primitifÂ: critères diagnostiques et de suivi. Revue Du Rhumatisme Monographies, 2010, 77, 108-113.	0.0	0
59	De nouvelles cibles cytokiniques dans la polyarthrite rhumatoÃ <sup>-</sup> de : le tocilizumab et les autres inhibiteurs des cytokines. Revue Du Rhumatisme (Edition Francaise), 2010, 77, S32-S40.	0.0	1
60	Innate immunity triggers IL-32 expression by fibroblast-like synoviocytes in rheumatoid arthritis. Arthritis Research and Therapy, 2010, 12, R135.	1.6	58
61	Incidence and Prevalence of Systemic Sclerosis: A Systematic Literature Review. Seminars in Arthritis and Rheumatism, 2008, 37, 223-235.	1.6	365
62	Nocardia discitis in an immunocompetent patient. Joint Bone Spine, 2007, 74, 207-209.	0.8	13